Arbutus Biopharma Corporation (ABUS) SEC Filings & Earnings Calls

Clinical hold removal reduces regulatory risk but does not guarantee clinical success or commercial viability.

“Clinical hold lifted, but AB-101 still requires clinical trial execution and eventual approval.”

Execution risk: tender offer not yet commenced and may not occur on described terms or at all.

“there can be no assurances that the Company will commence the tender offer on the terms described herein or at all” · word for word

European Patent Revocation

“On January 15, 2026, in a verbal decision, the Board of Appeal of the EPO revoked the '254 Patent.” · word for word

Contingent Payment Uncertainty

“Moderna is obligated to pay us and Genevant an additional aggregate contingent lump sum payment of $1.3 billion... upon a ruling that is favorable to us and Genevant in a limited appeal.” · word for word

Clinical Trial Risk

“We are currently developing imdusiran... for the treatment of chronic hepatitis B (cHBV).”

Revenue decline due to conclusion of Qilu partnership; reliance on settlement proceeds for capital return.

“Revenue decreased $9.7M due to recognizing all deferred revenue in prior year period upon partnership conclusion.”

Contingent payment of up to $1.3B depends on appellate ruling, which may not occur.

“Moderna is obligated to make an additional contingent lump sum payment of up to an aggregate $1.3 billion if certain events occur” · word for word

Revenue and profitability heavily dependent on one-time litigation settlement; core business remains clinical-stage with no approved products.

“Total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna” · word for word

Contingent Payment Risk

“In addition, Moderna is obligated to pay us and Genevant an additional aggregate contingent lump sum payment of $1.3 billion (the Contingent Settlement Payment) upon a ruling that is favorable to us and Genevant in a limited appeal... Under certain circumstances... if the Arbutus/Genevant §1498 Victory is subsequently overturned in Moderna’s favor in a final” · word for word

Pfizer/BioNTech Litigation Outcome Risk

“We continue to protect and defend our intellectual property, which is the subject of our ongoing lawsuit against Pfizer Inc. and BioNTech SE (collectively, Pfizer/BioNTech) for their use of our patented lipid nanoparticle (LNP) technology in their COVID-19 messenger ribonucleic acid interference (mRNA)-LNP vaccines.” · word for word

Clinical Trial Risk

“Our strategy, future operations, preclinical studies, clinical trials, and prospects; ... the potential for our product candidates to achieve their desired or anticipated outcomes;” · word for word

Clinical and regulatory risks remain; Fast Track does not guarantee approval.

“Fast Track program is designed to facilitate development and expedite review, but does not ensure approval.” · word for word

Clinical Hold on AB-101 IND

“It may take considerable time and expense to resolve the clinical hold that has been placed on our IND application of AB-101 by the FDA, and no assurance can be given that the FDA will remove the clinical hold.” · word for word

Patent Litigation Uncertainty

“We are involved in patent infringement lawsuits to protect and assert our intellectual property rights against large, well-capitalized companies and the United States, which requires that we continue to expend substantial resources, and we may not be successful in these proceedings.” · word for word

Contingent Settlement Payment Risk

“We face risks associated with the Contingent Settlement Payment under the Moderna Settlement Agreement.” · word for word

No Product Revenue

“We do not generate revenues from product sales and may never be profitable from operations.” · word for word

Dependence on Third-Party Manufacturers

“We rely exclusively on third parties to formulate and manufacture our product candidates, which exposes us to a number of risks that may delay development, regulatory approval and commercialization of our products.” · word for word

Contingent payment risk from Moderna settlement

“$1.3 billion contingent upon appellate ruling that Section 1498 does not bar claims”

Ongoing litigation with Pfizer/BioNTech

“On-going lawsuit against Pfizer/BioNTech for LNP technology infringement”

Contingent payment dependent on appeal outcome; potential repayment if overturned.

“if the Arbutus/Genevant § 1498 Victory is subsequently overturned... Arbutus/Genevant is required to return the Contingent Payment” · word for word

Litigation outcome uncertain; could result in significant damages or licensing revenue.

“Lawsuit seeks damages for patent infringement; court ruling on summary judgment could impact case trajectory.”

Litigation risk: Patent infringement case against Moderna; outcome uncertain; could result in significant damages or no recovery.

“Litigation filed; court ruling on motions; no final judgment.”

Financial risk: Company has limited revenue; litigation costs may be material.

“Known metrics show low revenue; litigation expenses not disclosed.”

Patent litigation risk: revocation of European patent may reduce potential damages or settlement value in European cases; appeal uncertain.

“Decision likely to affect case against Moderna in Switzerland and one UPC case; written decision expected in months.”

Litigation outcomes are uncertain; legal costs and potential adverse rulings could impact financials.

“Forward-looking statements caution about uncertainties in patent litigation.”

Litigation outcomes uncertain; Moderna trial in 2026, Pfizer claim construction favorable but not final.

“Moderna litigation U.S. trial scheduled for March 2026; Pfizer claim construction ruling in September 2025” · word for word

Cash burn continues with no near-term revenue catalyst; reliance on litigation or partnership.

“Cash $93.7M, down from $122.6M; operating cash use $35M in 9 months”

Patent litigation outcome uncertainty

“We cannot assure you that we will be successful in our patent infringement lawsuits against Moderna and Pfizer/BioNTech.”

Clinical trial failure risk

“Our product candidates may not achieve their desired or anticipated outcomes.”

Cash burn and financing risk

“We may need additional financing to fund our operations.”

Dependence on single product candidate

“Our business is highly dependent on the success of imdusiran.”

Regulatory approval risk

“We may not obtain necessary regulatory approvals.”